Iatrogenic Diabetes (Steroid-induced) - Symptoms, Causes, Treatment & Prevention

Overview

Iatrogenic diabetes—also called steroid‑induced diabetes mellitus (SIDM)—occurs when therapeutic glucocorticoids (e.g., prednisone, dexamethasone, methylprednisolone) raise blood glucose enough to meet the diagnostic criteria for diabetes. The condition is “iatrogenic” because it results from medical treatment rather than an inherent metabolic defect.

Glucocorticoids are prescribed for a wide range of conditions, including asthma, rheumatoid arthritis, inflammatory bowel disease, malignancies, and, more recently, severe COVID‑19. While they are life‑saving for many patients, their impact on glucose metabolism can be substantial.

Who It Affects

• Adults receiving high‑dose or long‑term oral glucocorticoids (≥20 mg prednisone equivalent per day for >2 weeks).
• Patients on intermittent high‑dose regimens (e.g., pulse therapy for autoimmune diseases).
• Children and adolescents receiving glucocorticoids for conditions such as leukemia, nephrotic syndrome, or cerebral edema.
• Individuals with pre‑existing risk factors for diabetes (obesity, family history, metabolic syndrome, prior gestational diabetes).

Prevalence

Estimates vary because screening practices differ, but large cohort studies suggest:

• ~10–30% of patients on chronic high‑dose steroids develop hyperglycemia meeting diabetes criteria (Mayo Clinic, 2023).
• In COVID‑19 patients treated with dexamethasone, new‑onset diabetes was reported in 14–19% of hospitalized adults (JAMA Netw Open, 2022).
• Children receiving glucocorticoids for acute lymphoblastic leukemia have a 20% incidence of transient hyperglycemia, with ~5% persisting beyond 6 months (Blood, 2021).

Symptoms

Many patients are asymptomatic at first; routine glucose checks often reveal the problem. When symptoms do appear, they resemble those of type 2 diabetes:

• Polyuria: frequent urination, especially at night.
• Polydipsia: excessive thirst despite adequate fluid intake.
• Polyphagia: increased hunger.
• Unexplained weight loss: despite normal or increased appetite.
• Fatigue: feeling unusually tired or weak.
• Blurred vision: caused by fluid shifts in the lens.
• Recurrent infections: especially fungal or urinary tract infections.
• Slow wound healing: cuts or sores that take longer to close.
• Ketosis symptoms (rare): nausea, vomiting, abdominal pain, fruity breath—suggesting diabetic ketoacidosis (DKA), more common in type 1 but can appear in severe steroid‑induced hyperglycemia.

Causes and Risk Factors

How Glucocorticoids Raise Blood Glucose

1. Increased hepatic gluconeogenesis: Steroids stimulate enzymes that produce glucose from amino acids and glycerol.
2. Peripheral insulin resistance: Muscle and adipose tissue become less responsive to insulin.
3. Impaired pancreatic β‑cell function: High steroid levels blunt insulin secretion.
4. Altered adipokine profile: Increases in leptin and resistin, decreasing insulin sensitivity.

Key Risk Factors

• Dosage & duration: ≥20 mg prednisone equivalents per day for >2 weeks is the classic threshold.
• Age: Risk rises after age 45.
• Obesity (BMI ≥ 30 kg/m²).
• Family history of type 2 diabetes.
• Pre‑existing impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).
• Ethnicity: Higher incidence in African‑American, Hispanic, South‑Asian, and Native American populations.
• Concurrent medications: Drugs that worsen insulin resistance (e.g., antipsychotics, tacrolimus).
• Pregnancy: Steroid use during pregnancy increases gestational diabetes risk.

Diagnosis

Diagnosis follows the same criteria as other forms of diabetes, but clinicians maintain a high index of suspicion when patients are on glucocorticoids.

Screening Recommendations

• Baseline: Fasting plasma glucose (FPG) or HbA1c before starting steroids.
• During therapy: Check FPG or random glucose ≥ 100 mg/dL (5.6 mmol/L) within 1‑2 weeks of initiating high‑dose steroids; repeat every 2‑4 weeks thereafter.
• Post‑therapy: Re‑evaluate 4‑6 weeks after discontinuation to determine if hyperglycemia persists.

Diagnostic Tests

• Fasting Plasma Glucose (FPG): ≥126 mg/dL (7.0 mmol/L) on two separate occasions.
• Oral Glucose Tolerance Test (OGTT): 2‑hour glucose ≥200 mg/dL (11.1 mmol/L).
• HbA1c: ≥6.5% (48 mmol/mol). Note: Short‑term steroid exposure may not immediately reflect in HbA1c.
• C‑peptide level: Helps differentiate between insulin deficiency and pure resistance when needed.
• Urine ketones: If symptoms suggest DKA.

Treatment Options

Treatment balances three goals: control hyperglycemia, minimize steroid side effects, and address underlying disease.

Medication Strategies

1. Metformin: First‑line for many patients; reduces hepatic glucose output and improves peripheral sensitivity. Start low (500 mg daily) and titrate.
2. Insulin: Preferred for:
   • Severe hyperglycemia (FPG >250 mg/dL or random >300 mg/dL).
   • Patients with contraindications to metformin (e.g., renal insufficiency).
   • Pregnant patients.
   Rapid‑acting or basal‑bolus regimens are common; dose often mirrors the steroid schedule (e.g., higher doses in the morning when steroid effect peaks).
3. SGLT2 inhibitors (e.g., empagliflozin): Can be added for cardiovascular/renal protection but watch for euglycemic DKA, especially if high‑dose steroids are used.
4. DPP‑4 inhibitors (e.g., sitagliptin): Useful when weight gain is a concern; modest glucose‑lowering effect.
5. GLP‑1 receptor agonists (e.g., liraglutide): Offer weight loss and cardiovascular benefit; can be considered if metformin insufficient.
6. Thiazolidinediones: Not first‑line due to fluid retention, which may aggravate steroid‑induced edema.

Lifestyle Interventions

• Diet: Emphasize low‑glycemic index carbs, high fiber, lean protein, and healthy fats. The Mediterranean pattern reduces insulin resistance.
• Physical activity: Aim for ≥150 min/week of moderate aerobic exercise plus resistance training 2‑3 times weekly.
• Weight management: Even a 5% weight loss can markedly improve glucose control.
• Stress reduction: Chronic stress can worsen hyperglycemia; techniques such as mindfulness or yoga are helpful.

Adjusting Steroid Therapy

If clinically feasible, physicians may:

• Switch to the lowest effective glucocorticoid dose.
• Use alternate‑day dosing.
• Choose a steroid with less glucocorticoid potency (e.g., budesonide for certain GI disorders).

Never alter prescribed steroids without medical guidance.

Living with Iatrogenic Diabetes (Steroid‑Induced)

Daily Management Tips

• Self‑monitoring: Check blood glucose 4–6 times/day when on high‑dose steroids (fasting, pre‑lunch, pre‑dinner, bedtime). Use a log or app to track trends.
• Medication timing: Align rapid‑acting insulin with the peak steroid effect (usually 4‑8 h after oral dose). Basal insulin may need a modest increase during the steroid course.
• Nutrition:
  • Spread carbohydrate intake evenly throughout the day.
  • Include protein and healthy fats at each meal to blunt post‑prandial spikes.
  • Avoid sugary beverages and large amounts of refined carbs.
• Exercise: Take short walks after meals; muscle activity improves glucose uptake.
• Hydration: Adequate water intake helps with polyuria.
• Medication review: Keep an updated list of all drugs (including over‑the‑counter) to alert healthcare providers to potential interactions.
• Follow‑up appointments: Schedule endocrine or primary‑care visits within 2 weeks of any change in steroid dose.

Psychosocial Support

Being diagnosed with diabetes while already managing another serious illness can be overwhelming. Consider:

• Diabetes education programs (often free at hospitals).
• Support groups—online or in‑person.
• Counseling for anxiety or depression, which occur in up to 30% of patients with chronic steroid therapy (Cleveland Clinic, 2022).

Prevention

While some steroid use is unavoidable, several strategies can reduce the risk of developing SIDM:

• Pre‑therapy screening: Identify impaired fasting glucose or metabolic syndrome before starting steroids.
• Lowest effective dose & shortest duration: Follow evidence‑based guidelines for each condition.
• Alternative agents: Non‑steroidal anti‑inflammatory drugs (NSAIDs), disease‑modifying antirheumatic drugs (DMARDs), or biologics may replace steroids in selected patients.
• Prophylactic metformin: Emerging data suggest starting metformin when high‑dose steroids are anticipated for >2 weeks can blunt glucose rise (Diabetes Care, 2023).
• Patient education: Teach patients to recognize early hyperglycemia symptoms and to report them promptly.

Complications

If hyperglycemia remains uncontrolled, steroid‑induced diabetes can lead to the same complications as other forms of diabetes:

• Acute: Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), severe infections.
• Chronic:
  • Microvascular: retinopathy, nephropathy, peripheral neuropathy.
  • Macrovascular: accelerated atherosclerosis, coronary artery disease, stroke.
  • Increased risk of osteomyelitis and skin ulceration due to impaired wound healing.
• Pregnancy outcomes: Higher rates of pre‑eclampsia, macrosomia, and neonatal hypoglycemia.
• Quality of life impact: Frequent monitoring, medication burden, and anxiety.

When to Seek Emergency Care

References

• Mayo Clinic. “Steroid‑induced diabetes.” Updated 2023.
• American Diabetes Association. “Standards of Care in Diabetes—2024.” Diabetes Care.
• JAMA Network Open. “Incidence of new‑onset diabetes in hospitalized COVID‑19 patients treated with dexamethasone.” 2022.
• Blood Journal. “Glucose metabolism in pediatric acute lymphoblastic leukemia treated with glucocorticoids.” 2021.
• Cleveland Clinic. “Psychological impact of chronic steroid therapy.” 2022.
• Diabetes Care. “Metformin prophylaxis for steroid‑induced hyperglycemia.” 2023.
• World Health Organization. “Global report on diabetes.” 2021.